Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigating cardiometabolic risk and chronobiology in autonomous adrenal cortisol secretion
2024-512100-19-00Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metyrapone in Mild hypercortisolism (SCS), Adrenal adenoma and cardiometabolic risk (CMR) (2 arms), sponsored by Medical University of Vienna. Primary endpoint: Hepatic lipid content. Started Oct 2024; status: completed.
02
Drugs
metyrapone
03
Conditions
Mild hypercortisolism (SCS)Adrenal adenomacardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2024-512100-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512100-19-00.